MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Operating income 2021–2025
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) annual operating income history from SEC filings — each fiscal year as reported.
-$244.8MFY2025 · since FY2021: -$4.6M → -$244.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$244.8M | -71.1% |
| FY2024 | -$143.1M | -164.4% |
| FY2023 | -$54.1M | +16.8% |
| FY2022 | -$65.1M | -1323.6% |
| FY2021 | -$4.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More MLTX financial trends
MLTX RevenueMLTX Net incomeMLTX Net marginMLTX Gross profitMLTX Gross marginMLTX Operating marginMLTX Operating cash flowMLTX Free cash flowMLTX Capital expendituresMLTX Return on equityMLTX Stock buybacksMLTX Dividends paidMLTX Total assetsMLTX Total liabilitiesMLTX Shareholders’ equityMLTX overview →